Cost-utility of respiratory syncytial virus prefusion F (RSVpreF) maternal vaccine for disease prevention among colombian infants.
- 1True Consulting S.A.S., Medellín, Colombia. [email protected].
- 2Independent Pediatrician and Researcher, Rionegro, Colombia.
Abstract
Background
Respiratory Syncytial Virus (RSV) is one of the leading causes of acute lower respiratory tract infections in Colombia, therefore, as no widespread antiviral exists, maternal immunization using RSV prefusion F protein vaccine (RSVpreF) represents a promising strategy. This study aims to evaluate the cost-utility of the RSVpreF maternal vaccine in preventing RSV infections among Colombian infants.Methods
We used a Markov model to simulate a Colombian birth cohort over a lifetime horizon, comparing maternal RSVpreF vaccination with no intervention, reflecting the current standard of care in Colombia. The model incorporated RSV-related outpatient visits, hospitalizations, and deaths. We collected data from clinical trials, peer-reviewed literature, and Colombian national health databases. Costs were analyzed from the perspective of the Colombian healthcare system, adjusted to 2024 USD, and we applied a 5% discount rate to both costs and outcomes. We used a willingness-to-pay (WTP) threshold of $ 7,491 per quality-adjusted life year (QALY). Sensitivity analyses, including one-way and probabilistic sensitivity analyses, were performed to evaluate the robustness of the results.Results
Maternal RSVpreF vaccination was associated with a reduction of approximately 25,781 RSV-related cases and an increase of 2,315 QALYs. The incremental cost-effectiveness ratio (ICER) was $ 2,322 per QALY, well below the WTP threshold. Sensitivity analyses identified vaccine effectiveness, vaccine cost and RSV hospitalization rates as the primary drivers of cost-effectiveness. The probabilistic sensitivity analysis indicated an 83.5% probability that the intervention would be cost-effective at the established WTP threshold.Conclusion
Maternal RSVpreF vaccination is a cost-effective intervention in Colombia, resulting in significant reductions in RSV-related morbidity and mortality, as well as in the economic burden on the healthcare system. The findings support the inclusion of maternal RSV vaccination in national immunization programs, promoting health equity in underserved communities.Clinical trial number
Not applicable.
Related
- A randomised, double-blind, multicentre, placebo-controlled phase 3 efficacy, safety, and immunogenicity study of an Ad26.RSV.preF/RSV prefusion F-protein vaccine for the prevention of respiratory syncytial virus-mediated lower respiratory tract disease in adults aged 60 years and older
- Uptake of Respiratory Syncytial Virus Prefusion F Protein Vaccination during Pregnancy and nirsevimab among Infants over Two Seasons in a Single Health System.
- Immunogenicity and Safety of Coadministration of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine and a COVID-19 mRNA Vaccine in Adult s Aged ≥50 Years: A Phase 3, Randomized, Noninferiority Trial
- Efficacy, Effectiveness, and Immunogenicity of the Respiratory Syncytial Virus Prefusion F Vaccine Administered During Pregnancy: Protocol for a Living Systematic Review and Meta-Analysis.
- Respiratory syncytial virus vaccination during pregnancy confers higher anti-RSV IgG concentration in neonatal cord than maternal blood
BibTeX
@article{ordonez2026costutility,
title = {{Cost-utility of respiratory syncytial virus prefusion F (RSVpreF) maternal vaccine for disease prevention among colombian infants.}},
author = {Jaime Ordóñez and Beatriz Ospina},
journal = {BMC health services research},
year = {2026},
month = aug,
doi = {10.1186/s12913-026-15139-0},
url = {https://europepmc.org/article/MED/42968145},
note = {CC BY},
}
RIS
TY - JOUR
TI - Cost-utility of respiratory syncytial virus prefusion F (RSVpreF) maternal vaccine for disease prevention among colombian infants.
AU - Jaime Ordóñez
AU - Beatriz Ospina
PY - 2026
DA - 2026/08/03
JO - BMC health services research
DO - 10.1186/s12913-026-15139-0
UR - https://europepmc.org/article/MED/42968145
AB - Background Respiratory Syncytial Virus (RSV) is one of the leading causes of acute lower respiratory tract infections in Colombia, therefore, as no widespread antiviral exists, maternal immunization using RSV prefusion F protein vaccine (RSVpreF) represents a promising strategy. This study aims to evaluate the cost-utility of the RSVpreF maternal vaccine in preventing RSV infections among Colombian infants.Methods We used a Markov model to simulate a Colombian birth cohort over a lifetime horizon, comparing maternal RSVpreF vaccination with no intervention, reflecting the current standard of care in Colombia. The model incorporated RSV-related outpatient visits, hospitalizations, and deaths. We collected data from clinical trials, peer-reviewed literature, and Colombian national health databases. Costs were analyzed from the perspective of the Colombian healthcare system, adjusted to 2024 USD, and we applied a 5% discount rate to both costs and outcomes. We used a willingness-to-pay (WTP) threshold of $ 7,491 per quality-adjusted life year (QALY). Sensitivity analyses, including one-way and probabilistic sensitivity analyses, were performed to evaluate the robustness of the results.Results Maternal RSVpreF vaccination was associated with a reduction of approximately 25,781 RSV-related cases and an increase of 2,315 QALYs. The incremental cost-effectiveness ratio (ICER) was $ 2,322 per QALY, well below the WTP threshold. Sensitivity analyses identified vaccine effectiveness, vaccine cost and RSV hospitalization rates as the primary drivers of cost-effectiveness. The probabilistic sensitivity analysis indicated an 83.5% probability that the intervention would be cost-effective at the established WTP threshold.Conclusion Maternal RSVpreF vaccination is a cost-effective intervention in Colombia, resulting in significant reductions in RSV-related morbidity and mortality, as well as in the economic burden on the healthcare system. The findings support the inclusion of maternal RSV vaccination in national immunization programs, promoting health equity in underserved communities.Clinical trial number Not applicable.
SN - 1472-6963
ER -